Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | DHODH | Q02127 | 13/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2406363 | 0.86 | MAPT (0.53) | CYP1A2MAPTCYP2C19DHODHMEN1 | |
| SCHEMBL468629 | 0.84 | DHODH (0.80) | DHODH | |
| SCHEMBL21379546 | 0.76 | MAPT (0.70) | CYP1A2MAPTCYP2C19MEN1GAA | |
| SCHEMBL29552260 | 0.75 | MAPT (0.52) | CYP1A2MAPTCYP2C19DGAT1RAB9A | |
| SCHEMBL2403929 | 0.75 | DHODH (0.67) | DHODH | |
| SCHEMBL2406388 | 0.75 | DHODH (0.64) | DHODH | |
| SCHEMBL28860458 | 0.74 | EGFR (0.54) | CYP1A2MAPTCYP2C19DGAT1 | |
| SCHEMBL25666147 | 0.74 | KCNH2 (0.52) | MAPTDHODHMEN1GAAKMT2A | |
| SCHEMBL24901393 | 0.73 | ADK (0.50) | CYP1A2MAPTCYP2C19DGAT1 | |
| SCHEMBL468594 | 0.72 | DHODH (1.00) | DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140005178-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2014-01-02 | — | — | US | claimed |
| WO-2012052180-A1 | COMBINATIONS COMPRISING DHODH INHIBITORS AND COX INHIBITORS | ALMIRALL, S.A. (ES) | 2012-04-26 | — | — | WO | claimed |
| WO-2012052179-A1 | AMINO DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE SKIN DISORDERS | ALMIRALL, S.A. (ES) | 2012-04-26 | — | — | WO | claimed |
| EP-2444088-A1 | Amino derivatives for the treatment of proliferative skin disorders | Almirall, S.A. (ES) | 2012-04-25 | — | — | EP | claimed |
| EP-2444086-A1 | Combinations comprising DHODH inhibitors and COX inhibitors | Almirall, S.A. (ES) | 2012-04-25 | — | — | EP | claimed |
| EP-2178840-B1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL SA (ES) | 2011-12-14 | — | — | EP | claimed |
| EP-2389197-A1 | COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS | Almirall S.A. (ES) | 2011-11-30 | — | — | EP | claimed |
| US-20110280831-A1 | COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2011-11-17 | — | — | US | claimed |
| US-20110253957-A1 | Compliant motion distribution system | FLEXSYS, INC. | 2011-10-20 | — | — | US | claimed |
| US-20110212945-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2011-09-01 | — | — | US | claimed |
| WO-2010083975-A1 | COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2010-07-29 | — | — | WO | claimed |
| EP-2210615-A1 | Combinations comprising methotrexate and DHODH inhibitors | Almirall, S.A. (ES) | 2010-07-28 | — | — | EP | claimed |
| EP-2178840-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | Almirall, S.A. (ES) | 2010-04-28 | — | — | EP | claimed |
| EP-2100881-A1 | Pyrimidyl- or pyridinylaminobenzoic acid derivatives | Laboratorios Almirall, S.A. (ES) | 2009-09-16 | — | — | EP | claimed |
| WO-2009021696-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2009-02-19 | — | — | WO | claimed |
| EP-2389197-B1 | COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS | ALMIRALL SA (ES) | 2014-06-18 | — | — | EP | disclosed |
| US-20140005178-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2014-01-02 | — | — | US | disclosed |
| EP-2100881-A1 | Pyrimidyl- or pyridinylaminobenzoic acid derivatives | Laboratorios Almirall, S.A. (ES) | 2009-09-16 | — | — | EP | disclosed |
| WO-2009021696-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009021696-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110280831-A1 | COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS | DHODH, CBR3, HRH4 | CYP1A2 875/4885MAPT 4772/4885CYP2C19 1466/4885 |
| US-20140005178-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | DHODH, DPYD, DLD | CYP1A2 362/4885MAPT 3751/4885CYP2C19 606/4885 |
| US-20110212945-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | DHODH, DPYD, DLD | CYP1A2 362/4885MAPT 3751/4885CYP2C19 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.